Literature DB >> 30910538

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.

Paola Bertuccio1, Matteo Malvezzi2, Greta Carioli2, Dana Hashim3, Paolo Boffetta4, Hashem B El-Serag5, Carlo La Vecchia2, Eva Negri6.   

Abstract

BACKGROUND & AIMS: Intrahepatic (ICC) and extrahepatic cholangiocarcinoma (ECC) have rarely been studied individually, probably due to difficulties in their diagnosis and certification. Mortality trends from these 2 neoplasms have been inconsistent over the last decades. The aim of this study was to analyze worldwide trends in mortality from ICC and ECC in selected countries.
METHODS: We extracted death certification data for ICC and ECC, and population estimates from the World Health Organization and Pan American Health Organization databases for 32 selected countries from Europe, the Americas, and Australasia from 1995 to 2016. We computed age-standardized (world population) mortality rates from ICC and ECC, and performed joinpoint regression analysis.
RESULTS: Mortality rates from ICC increased in all countries considered, with a levelling off over recent years in Germany (women), Italy (men), Argentina (men), the USA (men), Hong Kong (men), and Japan (both sexes). The highest rates in 2010-2014 (1.5-2.5/100,000 in men and 1.2-1.7/100,000 in women) were registered in Hong Kong, France, Austria, Spain, the UK, and Australia. The lowest rates (0.2-0.6/100,000 in both sexes) were registered in Latin American and eastern European countries. Mortality from ECC decreased in most of the countries considered, with rates below 1/100,000 in both sexes between 2010 and 2014, with the only exception being Japan (2.8/100,000 in men and 1.4/100,000 in women).
CONCLUSIONS: Increasing mortality from ICC was observed globally, due to trends in risk factors and possibly, in part, due to better disease classification. Mortality from ECC levelled off or decreased, most likely following the increased use of laparoscopic cholecystectomy. LAY
SUMMARY: Biliary tract cancers include intrahepatic cholangiocarcinoma (ICC) and extrahepatic cholangiocarcinoma (ECC), however there are some differences in their risk factors. Consequently, the distinction between ICC and ECC is important. Over the last few decades, mortality from ICC has tended to rise in several areas of the world, following the increased prevalence of its major risk factors. In contrast, mortality from ECC tended to decrease in most countries, following the increased use of laparoscopic cholecystectomy.
Copyright © 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Extrahepatic cholangiocarcinoma; Intrahepatic cholangiocarcinoma; Mortality; Trends; Worldwide

Mesh:

Year:  2019        PMID: 30910538     DOI: 10.1016/j.jhep.2019.03.013

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  91 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

2.  Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma.

Authors:  Emilien Loeuillard; Jingchun Yang; EeeLN Buckarma; Juan Wang; Yuanhang Liu; Caitlin Conboy; Kevin D Pavelko; Ying Li; Daniel O'Brien; Chen Wang; Rondell P Graham; Rory L Smoot; Haidong Dong; Sumera Ilyas
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

3.  Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.

Authors:  Jianzhen Lin; Xu Yang; Junyu Long; Songhui Zhao; Jinzhu Mao; Dongxu Wang; Yi Bai; Jin Bian; Lei Zhang; Xiaobo Yang; Anqiang Wang; Fucun Xie; Weiwei Shi; Huayu Yang; Jie Pan; Ke Hu; Mei Guan; Lin Zhao; Li Huo; Yilei Mao; Xinting Sang; Kai Wang; Haitao Zhao
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

4.  The 11th revision of the International Statistical Classification of Disease and Related Health Problems and Cholangiocarcinoma.

Authors:  Shijie Cai; Shivan Sivakumar
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

5.  Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation.

Authors:  Edward Christopher Dee; Morgan E Freret; Nora Horick; Ann C Raldow; Lipika Goyal; Andrew X Zhu; Aparna R Parikh; David P Ryan; Jeffrey W Clark; Jill N Allen; Cristina R Ferrone; Carlos Fernandez-Del Castillo; Kenneth K Tanabe; Lorraine C Drapek; Theodore S Hong; Motaz Qadan; Jennifer Y Wo
Journal:  Ann Surg Oncol       Date:  2020-08-01       Impact factor: 5.344

Review 6.  Current challenges to underpinning the genetic basis for cholangiocarcinoma.

Authors:  Antonio Cigliano; Xin Chen; Diego F Calvisi
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-04-23       Impact factor: 3.869

7.  Hepatic stellate cells promote intrahepatic cholangiocarcinoma progression via NR4A2/osteopontin/Wnt signaling axis.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Cheng Zhou; Mei-Xia Zhang; Yong Yi; Jin-Long Huang; Wei Gan; Juan Zhang; Su-Su Zheng; Bo-Heng Zhang; Shuang-Jian Qiu
Journal:  Oncogene       Date:  2021-03-19       Impact factor: 9.867

Review 8.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 9.  Cholangiocarcinoma: bridging the translational gap from preclinical to clinical development and implications for future therapy.

Authors:  Leonardo Baiocchi; Keisaku Sato; Burcin Ekser; Lindsey Kennedy; Heather Francis; Ludovica Ceci; Ilaria Lenci; Domenico Alvaro; Antonio Franchitto; Paolo Onori; Eugenio Gaudio; Chaodong Wu; Sanjukta Chakraborty; Shannon Glaser; Gianfranco Alpini
Journal:  Expert Opin Investig Drugs       Date:  2020-12-08       Impact factor: 6.206

10.  Identification of Mutator-Derived Alternative Splicing Signatures of Genomic Instability for Improving the Clinical Outcome of Cholangiocarcinoma.

Authors:  Zijing Lin; Jianping Gong; Guochao Zhong; Jiejun Hu; Dong Cai; Lei Zhao; Zhibo Zhao
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.